Latest / Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Tirzepatide for Weight Loss and Lowering HbA1c with Juan Frias, MD
This episode of the Endocrine Outlook features a conversation with Juan Frias, MD, medical director of the National Research Institute. Frias is also the principal investigator of the SURPASS-2 trial which examined Eli Lilly’s Dual GLP1/GIP agonist tirzepatide against 1mg semaglutide for glucose control and weight loss in patients with diabetes.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.